CXCR2 and metabolic dysfunction-associated steatohepatitis: These data provide evidence that combined therapeutic targeting of CXCR2+ neutrophils and the PD1-PDL1 immune checkpoint remodels the NASH-HCC tumour immune microenvironment, including the generation of locally proliferating immature NeP in close physical association with cytotoxic T cells.